Patent 6987093 Issued on January 17, 2006. Estimated Expiration Date: July 25, 2023. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
The present invention relates to a method of treating a bacterial respiratory or acute otitis media infections in humans by administering a single dose of azithromycin wherein the dose is about 40 mg/kg body weight or greater.
Other References
Block et al., “Single Dose Azithromycin (30 mg/kg) in Acute Otitis Media”, 38th annual meeting of the Infectious Disease Society of america, New Orleans, La., Sep. 7-10, 2000.
P/S/L Consulting Group, Inc., “Single-Dose Zithromax (azithromycin) as effective as 10 days of Augmentin (Amozcillin/Clavulenate) for Otitis Media”, Doctor's, Guide; Sep. 14, 2000.
Law et al., “Single-Dose Azithromycin for Respiratory Tract Infections”, The Annals of Pharmacotherapy, vol. 38, pp 433-439, Mar. 2004.
Arguedas, A., Single-Dose Therapy in Otitis Media, Poster Presentation at 9th European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, Mar. 21-24, 1999, Clin. Microbiol. Infect. 1999:5 (Supp. Mar. 3):28 (Abstr).
S. Block et al., Single-Dose Azithromycin (30 mg/kg) in Acute Otitis Media, 38th Annual Meeting of the Infectious Disease Society of America, New Orleans, LA, Sep. 7-10, 2000 (Abstract 174).
P/S/L Consulting Group Inc., Single-Dose Zithromax (Azithromycin) as Effective as 10 Days of Augmentin (Amoxcillin/Clavulenate) for Otitis Media, Doctor's Guide; Sep. 14, 2000.
FDA Briefing Package: Zithromax® (Azithromycin) Oral Suspension Single-Dose and Three Day Treatment of Acute Otitis Media, Anti-Infective Drugs Advisory Committee, Nov. 7, 2001.
Schonwald, S., et al., Infection, Germany, vol. 27, No. 3, May 1999, pp. 198-202 XP008018295.
Amsden, G.W., et al., The J. of Antimicrobial Chemotherapy, 47(1), pp. 61-66 (2001) XP001159703.
Mulier O., The J. of Antimicrobial Chemotherapy, England, Jun. 1993, vol. 31, suppl. E, Jun. 1993, pp. 137-146 XP008018300.
Nightingale C.H., et al., J. of Infectious Disease Pharmacotherapy 1999, vol. 4, No. 1, pp. 17-24 XP008018297.
Aoki N., Japanese Journal of Chemotherapy 1995, Japan, vol. 43, No. Suppl 6, pp. 234-238 XP008018296.
Morris, D.L., et al., vol. 10, No. 10., Oct. 1991, pp. 859-861, European J. of Clinical Microbiology & Infectious Disease: Official Publication of the European Society of Clinical Microbiology, Germany XP008018299.
Klepser, M., et al., International J. of Antimicrobial Agents, vol. 17, No. Supp 1, Jun. 2001, p. S157, 22nd International Congress of Chemotherapy; Amsterdam, Jun. 30-Jul. 3, 2001 XP002244592.
July 25, 2023. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
